Research Article| Volume 49, ISSUE 1, P51-57, September 24, 2004

Postmenopausal hormone therapy and the risk of breast cancer

A clinician’s view


      Reports from the Women’s Health Initiative (WHI) and the Million Women Study have indicated that postmenopausal hormone therapy increases the risk of breast cancer. At this point in time, it is not certain whether these data reflect a small increase in risk or an impact of hormone therapy on pre-existing tumors. The purpose of this review is to provide an analysis of the epidemiologic data that can help the clinician inform patients and assist patients in their decision-making.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health initiative randomized controlled trial. JAMA 2002;288:321–33.

        • Chlebowski R.T.
        • Hendrix S.L.
        • Langer R.D.
        • et al.
        Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women’s Health Initiative Randomized Trial.
        JAMA. 2003; 289: 3243-3253
        • Li C.I.
        • Malone K.E.
        • Porter P.L.
        • et al.
        Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
        JAMA. 2003; 289: 3254-3263
        • Li C.I.
        • Anderson B.O.
        • Daling J.R.
        • Moe R.E.
        Trends in incidence rates of invasive lobular and ductal breast carcinoma.
        JAMA. 2003; 289: 1421-1424
        • Carney P.A.
        • Miglioretti D.L.
        • Yankaskas B.C.
        • et al.
        Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography.
        Ann. Intern. Med. 2003; 138: 168-175
        • Rutter C.M.
        • Mandelson M.T.
        • Laya M.B.
        • Seger D.J.
        • Taplin S.
        Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy.
        JAMA. 2001; 285: 171-176
        • Berkowitz J.E.
        • Gatewood O.M.B.
        • Goldblum L.E.
        • Gayler B.W.
        Hormonal replacement therapy: mammographic manifestations.
        Radiology. 1990; 174: 199-201
        • Harvey J.A.
        • Pinkerton J.V.
        • Herman C.R.
        Short-term cessation of hormone replacement therapy and improvement of mammographic specificity.
        J. Natl. Cancer Inst. 1997; 89: 1623-1625
      2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27.

      3. American Cancer Society.; 2003.

      4. National Statistics UK.; 2003.

        • Banks E.
        Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review.
        J. Med. Screen. 2001; 8: 29-35
        • Séradour B.
        • Estève J.
        • Heid P.
        • Jacquemier J.
        Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhône programme.
        J. Med. Screen. 1999; 6: 99-102
        • Salminen T.M.
        • Saarenmaa I.E.
        • Heikkilä M.M.
        • Hakama M.
        Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy?.
        Acta Oncol. 2000; 39: 969-972
        • Laya M.B.
        • Larson E.B.
        • Taplin S.H.
        • et al.
        Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.
        J. Natl. Cancer Inst. 1996; 88: 643-649
        • Rosenberg R.D.
        • Hunt W.C.
        • Williamson M.R.
        • et al.
        Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico.
        Radiology. 1998; 209: 511-518
        • Litherland J.C.
        • Stallard S.
        • Hole D.
        • Cordiner C.
        The effect of hormone replacement therapy on the sensitivity of screening mammograms.
        Clin. Radiol. 1999; 54: 285-288
        • Kavanagh A.M.
        • Mitchell H.
        • Giles G.G.
        Hormone replacement therapy and accuracy of mammographic screening.
        Lancet. 2000; 355: 270-274
        • Moy L.
        • Slanetz P.J.
        • Yeh E.D.
        • Moore R.H.
        • Rafferty E.A.
        • Kopans D.B.
        Hormone replacement therapy rarely complicates or alters interpretation on screening mammography: a prospective analysis.
        Radiology. 2000; 217 (Abstract): 446
        • Sendag F.
        • Terek M.C.
        • Õzsener S.
        Mammographic density changes during different postmenopausal hormone replacement therapies.
        Fertil. Steril. 2001; 76: 445-450
        • Bergkvist L.
        • Adami H.O.
        • Persson I.
        • Bergstrom R.
        • Krusemo U.B.
        Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen–progestogen replacement therapy.
        Am. J. Epidemiol. 1989; 130: 221-227
        • Hunt K.
        • Vessey M.
        • McPherson K.
        Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis.
        Br. J. Obstet. Gynaecol. 1990; 97: 1080
        • Henderson B.E.
        • Paganini-Hill A.
        • Ross R.K.
        Decreased mortality in users of estrogen replacement therapy.
        Arch. Intern. Med. 1991; 151: 75-78
        • Persson I.
        • Yuen J.
        • Bergkvist L.
        • Schairer C.
        Cancer incidence and mortality in women receiving estrogen and estrogen–progestin replacement therapy—long-term follow-up of a Swedish cohort.
        Int. J. Cancer. 1996; 67: 327-332
        • Willis D.B.
        • Calle E.E.
        • Miracle-McMahill H.L.
        • Heath Jr., C.W.
        Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States.
        Cancer Causes Control. 1996; 7: 449-457
        • Grodstein F.
        • Stampfer M.J.
        • Colditz G.A.
        • et al.
        Postmenopausal hormone therapy and mortality.
        New Engl. J. Med. 1997; 336: 1769-1775
        • Sellers T.A.
        • Mink P.J.
        • Cerhan J.R.
        • et al.
        The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.
        Ann. Intern. Med. 1997; 127: 973-980
        • Schairer C.
        • Gail M.
        • Byrne C.
        • et al.
        Estrogen replacement therapy and breast cancer survival in a large screening study.
        J. Natl. Cancer Inst. 1999; 91: 264-270
        • Fowble B.
        • Hanlon A.
        • Greedman G.
        Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
        J. Clin. Oncol. 1999; 17: 1680-1688
        • Jernström H.
        • Frenander J.
        • Fernö M.
        • Olsson H.
        Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.
        Br. J. Cancer. 1999; 80: 1453-1458
        • Nanda K.
        • Bastian L.A.
        • Schulz K.
        Hormone replacement therapy and the risk of death from breast cancer: a systematic review.
        Am. J. Obstet. Gynecol. 2002; 186: 325-334
        • Bonnier P.
        • Romain S.
        • Giacalone P.L.
        • Laffargue F.
        • Martin P.M.
        • Piana L.
        Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy.
        Obstet. Gynecol. 1995; 85: 11
        • Magnusson C.
        • Holmberg L.
        • Norden T.
        • Lindgren A.
        • Persson I.
        Prognostic characteristics in breast cancers after hormone replacement therapy.
        Breast Cancer Res. Treat. 1996; 38: 325-334
        • Holli K.
        • Isola J.
        • Cuzick J.
        Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.
        J. Clin. Oncol. 1998; 16: 3115-3120
        • O’Connor I.F.
        • Shembekar M.V.
        • Shousha S.
        Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.
        J. Clin. Pathol. 1998; 51: 935-938
        • Salmon R.J.
        • Ansquer Y.
        • Asselain B.
        • Languille O.
        • Lesec G.
        • Remvikos Y.
        Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause.
        Oncol. Rep. 1999; 6: 699-703
        • Bilimoria M.M.
        • Winchester D.J.
        • Sener S.F.
        • Motykie G.
        • Sehgal U.L.
        • Winchester D.P.
        Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics.
        Ann. Surg. Oncol. 1999; 6: 200-207
        • Cheek J.
        • Lacy J.
        • Toth-Fejel S.
        • Morris K.
        • Calhoun K.
        • Pommier R.F.
        The impact of hormone replacement therapy on the detection and stage of breast cancer.
        Arch. Surg. 2002; 137: 1015-1019
      5. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004;291:1707–12.

        • Stefanick M.L.
        • Cochrane B.B.
        • Hsia J.
        • Barad D.H.
        • Liu J.H.
        • Johnson S.R.
        The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants.
        Ann. Epidemiol. 2003; 13: S78-S86